17,261 trials
Diabetic Peripheral Neuropathy
Primary: Mean Change From Baseline to Week 5 in Average Daily Pain Score (ADPS) Following Treatment With DS-5565 Compared to Pregabalin and Placebo — -1.86; -1.79; -2.04; -2.32…
Neoplastic Meningitis
Primary: Cerebrospinal Fluid (CSF) Response Rate: Percentage of Participants Positive for Tumor Cells — 93 percentage of participants
Psoriasis
Primary: Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4 — 2.38; -4.76; 2.48; -4.17 Percent Change
Cocaine Addiction
Primary: Cue-induced Craving After Lidocaine/Saline Administration. — 31.7; 17.3; 22.7 units on a scale
Gastrinoma · Glucagonoma · Insulinoma
Primary: Radiographic Response (RR) — 9; 0; 9; 9 Participants
Paroxysmal Supraventricular Tachycardia (PSVT)
Primary: The Percentage of Subjects Successfully Converted From PSVT to Sinus Rhythm Within 15 Minutes of Study Drug Administration — 20; 15; 20; 13 Participants — p=<0.05
Prostate Cancer
Primary: Overall Clinical Benefit — 1; 4; 1; 2 Participants
Pancreatic Tumours · Midgut Neuroendocrine Tumours
Primary: Median Progression Free Survival (PFS) — 5.6; 8.3 months
Hyperlipidemias · Hypertension
Primary: The Difference in Serum LDL-C From Baseline to Week 12 Between Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng Extract) and Placebo After 12 Weeks of…
Peripheral T-cell Lymphoma · Cutaneous T-cell Lymphoma
Primary: Global Composite Response (Skin, Blood, Lymph Nodes)as Determined by Skin Evaluations, Blood Counts and PET/CT Imaging — 260; 260; 232 days
Graft vs Host Disease · Hematopoietic Stem Cell Transplantation
Primary: Percentage of Patients With Grade II-IV Acute GvHD by Day +100 Following Transplant — 94.4 percentage of participants
S. Aureus Oropharyngeal Colonization
Primary: Number of Participants With Eradiction of S. Aureus From the Oropharyngeal at 7 Days — 18; 7 Participants
Human Immunodeficiency Virus
Primary: Changes in sCD14 After 9 Months of Treatment With Aspirin or Atorvastatin — -0.131; -0.09 pg/mL — p=>0.05
Lymphoma · Disorder Related to Bone Marrow Transplantation
Primary: Participant's Response According to Physician's Global Assessment of Clinical Condition (PGA) — 19; 6; 0; 0 participants
Merkel Cell Carcinoma
Primary: MLN01283 Maximum Tolerated Dose (MTD) [Phase I] — 3 mg